Safety Study of Abatacept in Rheumatoid Arthritis Participants
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
A observational study to assess whether biologic disease-modifying (BDM) treatment initiation with abatacept for rheumatoid arthritis is associated with an increased risk of serious infection and cancer
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Rheumatoid arthritis (RA) participant, population-based cohort study approach within the US-based Truven MarketScan population and Supplemental US Medicare database
Patient initiates BDM treatment with at least one claim for the treatment. Patients will be presumed to be new users of a treatment if there is no claim for the drug or any other BDM in the 180 days prior to the cohort entry date
Patient has at least two diagnoses for RA in the patient's history prior to and including the entry date or within the 180 days after the entry date
Patient is aged 18 years or older on the entry date
Patient was enrolled in the database for at least 180 days before the entry date
Patient is younger than 18 years on the entry date
Patients who receive abatacept and another biologic simultaneously
Patients who have an outcome diagnosis in the baseline period will be excluded from the cohort analyses for that outcome
Other protocol defined inclusion/exclusion criteria could apply